Vocal cord paralysis during the treatment of mantle cell lymphoma with vincristine
- PMID: 23338712
- DOI: 10.1007/s11096-013-9751-6
Vocal cord paralysis during the treatment of mantle cell lymphoma with vincristine
Abstract
Case description: We present a case of a seventy-eight year-old man who developed vocal cord paralysis without any sign of peripheral neuropathy during the treatment of Mantle Cell Lymphoma. He first presented in 2008 with a few bilateral small inguinal lymph nodes. Inguinal lymph node biopsy demonstrated Mantle Cell Lymphoma. Flow cytometry studies of peripheral blood and bone marrow cells were compatible with Mantle Cell Lymphoma. R-CHOP chemotherapy triweekly (Rituximab; Cyclophosphamide; Adriamycin; Vincristine; and Methylprednisolone) was planned. At the end of the second cycle, the patient complained of hoarseness without any symptoms of dysphagia or odynophagia. Direct flexible laryngoscopy showed bilateral vocal cord paralysis. Vincristine was discontinued and the patient's voice gradually resolved in about 4 months.
Conclusion: Vincristine may cause peripheral, autonomic and cranial neuropathies. However cranial nerve involvement is quite uncommon.
Similar articles
-
Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.Clin Adv Hematol Oncol. 2014 Aug;12(8 Suppl 16):9-11. Clin Adv Hematol Oncol. 2014. PMID: 25768994 No abstract available.
-
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.
-
[Vocal cord paralysis secondary to vincristine].Rev Neurol (Paris). 2012 May;168(5):464-5. doi: 10.1016/j.neurol.2011.09.013. Epub 2012 Mar 3. Rev Neurol (Paris). 2012. PMID: 22387202 French. No abstract available.
-
What is the optimal initial management of the older MCL patient?Best Pract Res Clin Haematol. 2018 Mar;31(1):99-104. doi: 10.1016/j.beha.2017.07.006. Epub 2017 Jul 19. Best Pract Res Clin Haematol. 2018. PMID: 29452672 Review.
-
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.Lancet Haematol. 2020 Apr;7(4):e295-e308. doi: 10.1016/S2352-3026(20)30031-4. Epub 2020 Mar 2. Lancet Haematol. 2020. PMID: 32135128
Cited by
-
The first reported case of vincristine-induced unilateral vocal cord palsy in an adult patient with HIV-associated Burkitt-like lymphoma being treated with dose-escalated R-EPOCH.Clin Case Rep. 2018 Dec 18;7(2):272-274. doi: 10.1002/ccr3.1964. eCollection 2019 Feb. Clin Case Rep. 2018. PMID: 30847188 Free PMC article.
-
Vincristine-Induced Bilateral Vocal Cord Palsy in an Adult Male With Diffuse Large B-Cell Lymphoma.Cureus. 2021 Oct 8;13(10):e18591. doi: 10.7759/cureus.18591. eCollection 2021 Oct. Cureus. 2021. PMID: 34765356 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials